Genotyping and immunohistochemistry of gastrointestinal stromal tumors

An update

Brian P. Rubin, Michael Heinrich

    Research output: Contribution to journalArticle

    21 Citations (Scopus)

    Abstract

    Gastrointestinal stromal tumors (GISTs) were originally thought to harbor either KIT or platelet-derived growth factor receptor A (PDGFRA) mutations only. However, more recent discoveries have highlighted additional, less common oncogenic driver mutations including NF1, BRAF, and succinate dehydrogenase (SDH) mutations. Genotyping GISTs has become more important since not all genotypes respond equally to FDA-approved tyrosine kinase inhibitors. GIST is a paradigm for personalized cancer therapy. Recent studies demonstrate how immunohistochemistry can be used both to diagnose GIST and to screen for specific mutations. DOG1 is particularly useful in the diagnosis of KIT-negative GIST, including tumors with PDGFRA mutations, which can also potentially be identified by immunohistochemistry for PDGFRA. SDHB immunohistochemistry is useful in characterizing GISTs with SDHA-D mutations, whereas SDHA immunohistochemistry is able to identify SDHA mutant GISTs.

    Original languageEnglish (US)
    Pages (from-to)392-399
    Number of pages8
    JournalSeminars in Diagnostic Pathology
    Volume32
    Issue number5
    DOIs
    StatePublished - Sep 1 2015

    Fingerprint

    Gastrointestinal Stromal Tumors
    Immunohistochemistry
    Platelet-Derived Growth Factor Receptors
    Mutation
    Succinate Dehydrogenase
    Protein-Tyrosine Kinases
    Neoplasms
    Genotype

    Keywords

    • BRAF
    • GIST
    • KIT
    • NF1
    • Platelet-derived growth factor receptor A
    • Succinate Dehydrogenase

    ASJC Scopus subject areas

    • Pathology and Forensic Medicine

    Cite this

    Genotyping and immunohistochemistry of gastrointestinal stromal tumors : An update. / Rubin, Brian P.; Heinrich, Michael.

    In: Seminars in Diagnostic Pathology, Vol. 32, No. 5, 01.09.2015, p. 392-399.

    Research output: Contribution to journalArticle

    @article{2af87e2f148e4b429578a72877f01117,
    title = "Genotyping and immunohistochemistry of gastrointestinal stromal tumors: An update",
    abstract = "Gastrointestinal stromal tumors (GISTs) were originally thought to harbor either KIT or platelet-derived growth factor receptor A (PDGFRA) mutations only. However, more recent discoveries have highlighted additional, less common oncogenic driver mutations including NF1, BRAF, and succinate dehydrogenase (SDH) mutations. Genotyping GISTs has become more important since not all genotypes respond equally to FDA-approved tyrosine kinase inhibitors. GIST is a paradigm for personalized cancer therapy. Recent studies demonstrate how immunohistochemistry can be used both to diagnose GIST and to screen for specific mutations. DOG1 is particularly useful in the diagnosis of KIT-negative GIST, including tumors with PDGFRA mutations, which can also potentially be identified by immunohistochemistry for PDGFRA. SDHB immunohistochemistry is useful in characterizing GISTs with SDHA-D mutations, whereas SDHA immunohistochemistry is able to identify SDHA mutant GISTs.",
    keywords = "BRAF, GIST, KIT, NF1, Platelet-derived growth factor receptor A, Succinate Dehydrogenase",
    author = "Rubin, {Brian P.} and Michael Heinrich",
    year = "2015",
    month = "9",
    day = "1",
    doi = "10.1053/j.semdp.2015.02.017",
    language = "English (US)",
    volume = "32",
    pages = "392--399",
    journal = "Seminars in Diagnostic Pathology",
    issn = "0740-2570",
    publisher = "W.B. Saunders Ltd",
    number = "5",

    }

    TY - JOUR

    T1 - Genotyping and immunohistochemistry of gastrointestinal stromal tumors

    T2 - An update

    AU - Rubin, Brian P.

    AU - Heinrich, Michael

    PY - 2015/9/1

    Y1 - 2015/9/1

    N2 - Gastrointestinal stromal tumors (GISTs) were originally thought to harbor either KIT or platelet-derived growth factor receptor A (PDGFRA) mutations only. However, more recent discoveries have highlighted additional, less common oncogenic driver mutations including NF1, BRAF, and succinate dehydrogenase (SDH) mutations. Genotyping GISTs has become more important since not all genotypes respond equally to FDA-approved tyrosine kinase inhibitors. GIST is a paradigm for personalized cancer therapy. Recent studies demonstrate how immunohistochemistry can be used both to diagnose GIST and to screen for specific mutations. DOG1 is particularly useful in the diagnosis of KIT-negative GIST, including tumors with PDGFRA mutations, which can also potentially be identified by immunohistochemistry for PDGFRA. SDHB immunohistochemistry is useful in characterizing GISTs with SDHA-D mutations, whereas SDHA immunohistochemistry is able to identify SDHA mutant GISTs.

    AB - Gastrointestinal stromal tumors (GISTs) were originally thought to harbor either KIT or platelet-derived growth factor receptor A (PDGFRA) mutations only. However, more recent discoveries have highlighted additional, less common oncogenic driver mutations including NF1, BRAF, and succinate dehydrogenase (SDH) mutations. Genotyping GISTs has become more important since not all genotypes respond equally to FDA-approved tyrosine kinase inhibitors. GIST is a paradigm for personalized cancer therapy. Recent studies demonstrate how immunohistochemistry can be used both to diagnose GIST and to screen for specific mutations. DOG1 is particularly useful in the diagnosis of KIT-negative GIST, including tumors with PDGFRA mutations, which can also potentially be identified by immunohistochemistry for PDGFRA. SDHB immunohistochemistry is useful in characterizing GISTs with SDHA-D mutations, whereas SDHA immunohistochemistry is able to identify SDHA mutant GISTs.

    KW - BRAF

    KW - GIST

    KW - KIT

    KW - NF1

    KW - Platelet-derived growth factor receptor A

    KW - Succinate Dehydrogenase

    UR - http://www.scopus.com/inward/record.url?scp=84940447192&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84940447192&partnerID=8YFLogxK

    U2 - 10.1053/j.semdp.2015.02.017

    DO - 10.1053/j.semdp.2015.02.017

    M3 - Article

    VL - 32

    SP - 392

    EP - 399

    JO - Seminars in Diagnostic Pathology

    JF - Seminars in Diagnostic Pathology

    SN - 0740-2570

    IS - 5

    ER -